OncoMatch

OncoMatch/Clinical Trials/NCT07111507

A Study of Tarlatamab for People With Prostate Cancer

Is NCT07111507 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tarlatamab for metastatic prostate cancer.

Phase 2RecruitingMemorial Sloan Kettering Cancer CenterNCT07111507Data as of May 2026

Treatment: Tarlatamab — The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Biomarker criteria

Required: DLL3 positive expression (50% or more of tumor cells with dll3 expression by ihc)

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Max 2 prior lines
Min 1 prior line

Must have received: androgen-deprivation therapy — metastatic

Serum testosterone ≤ 50 ng/dL with ongoing androgen-deprivation therapy (ADT) or de novo small cell NEPC (neither testosterone levels nor ADT are required in participants with de novo small cell NEPC)

Must have received: platinum-based chemotherapy — de novo small cell NEPC

Participants with de novo small cell NEPC are required to have received prior platinum-based chemotherapy or be ineligible for this treatment.

Cannot have received: DLL3-targeting treatment

Prior DLL3-targeting treatment

Lab requirements

Blood counts

ANC ≥ 1,500/μL; Hemoglobin ≥9g/dL; Platelet count ≥75,000/μL

Kidney function

CrCl ≥ 30 mL/min using Cockroft Gault or MDRD calculation

Liver function

Bilirubin ≤ 1.5 ULN or < 2 if liver metastases or Gilbert's disease; SGOT (AST) < 3 x ULN or < 5 if liver metastases; SGPT (ALT) < 3 x ULN or < 5 if liver metastases

Normal organ function with acceptable initial laboratory values within 14 days of treatment start. ANC ≥ 1,500/μL; Hemoglobin ≥9g/dL; Platelet count ≥75,000/μL; Bilirubin ≤ 1.5 ULN or < 2 if liver metastases or Gilbert's disease; SGOT (AST) < 3 x ULN or < 5 if liver metastases; SGPT (ALT) < 3 x ULN or < 5 if liver metastases; CrCl ≥ 30 mL/min using Cockroft Gault or MDRD calculation

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only) · San Diego, California
  • University of California San Francisco · San Francisco, California
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify